Accueil   Diary - News   All news Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT

Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT

 

Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT, a premium, complete integrated service offer for radiopharmaceuticals drug discovery and generation

 

New integrated drug discovery offer in nuclear medicine enables specialized partners to provide pharmaceutical industry with a unique service solution for theranostic drug development, from drug discovery through to clinical phases.

 

Dijon, France, July 1, 2021, 6pm CET – ONCODESIGN (ALONC -FR0011766229), a French biopharmaceutical company dedicated to precision medicine, Covalab (Bron, France), a biotechnology company specializing in the development and production of custom antibodies, CheMatech (Dijon, France), the European leader in the design, synthesis and supply of chelating agents and ABX-CRO (Dresden, Germany), the globally leading full-service CRO for molecular imaging and radiotherapy, today announce their partnership. This strategic collaboration will launch the DRIVE™-MRT (Molecular RadioTherapy) solution. This innovative, premium service offer for therapeutic development is unique in nuclear medicine; it encompasses the full drug discovery process of theranostics, from therapeutic target validation, radiolabeled biological vector generation, lead optimization, preclinical candidate drug generation and IND, to the design and management of clinical trials.

 

Read the press release